Eli Lilly Alzheimer’s Drug Delayed as FDA Plans Advisory Panel Meeting
Wall Street Journal
Eli Lilly said theFDA would hold an advisory committee meeting on its proposed Alzheimer’s disease drug donanemab, likely delaying the agency’s decision on whether to approve the drug.